Drug news
Vytorin recommended for reduction of CV risk in CKD patients
A panel of outside experts at the FDA has recommended the expanded use of Vytorin
(ezetimibe and simvastatin) from Merck inc. at the 10/20mg dose as a treatment for patients with chronic kidney disease (CKD not on dialysis. This would be the first drug for this indication, if approved. The recommendation is based on a review of data from the SHARP study which demonstrated that Vytorin reduced the risk of major vascular events by 16% versus placebo in patients with advanced CKD without a history of myocardial infarction or coronary revascularization.
.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins